These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

853 related articles for article (PubMed ID: 28947363)

  • 41. Association of clinical and inflammatory markers with small bowel capsule endoscopy findings in Crohn's disease.
    Mitselos IV; Katsanos KH; Tatsioni A; Skamnelos A; Eliakim R; Tsianos EV; Christodoulou DK
    Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):861-867. PubMed ID: 29697457
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Faecal Lactoferrin, Calprotectin, PMN-elastase, CRP, and White Blood Cell Count as Indicators for Mucosal Healing and Clinical Course of Disease in Patients with Mild to Moderate Ulcerative Colitis: Post Hoc Analysis of a Prospective Clinical Trial.
    Langhorst J; Boone J; Lauche R; Rueffer A; Dobos G
    J Crohns Colitis; 2016 Jul; 10(7):786-94. PubMed ID: 26874351
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease.
    Jones J; Loftus EV; Panaccione R; Chen LS; Peterson S; McConnell J; Baudhuin L; Hanson K; Feagan BG; Harmsen SW; Zinsmeister AR; Helou E; Sandborn WJ
    Clin Gastroenterol Hepatol; 2008 Nov; 6(11):1218-24. PubMed ID: 18799360
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [The Capsule Endoscopy Crohn's Disease Activity Index, clinical activity and fecal calprotectin level in patients with isolated small intestine lesions].
    Timerbulatov MV; Grishina EE; Aitova LR; Senderovich EI; Ziganshin TM
    Khirurgiia (Mosk); 2021; (9):63-70. PubMed ID: 34480457
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of disease location on fecal calprotectin levels in Crohn's disease.
    Gecse KB; Brandse JF; van Wilpe S; Löwenberg M; Ponsioen C; van den Brink G; D'Haens G
    Scand J Gastroenterol; 2015 Jul; 50(7):841-7. PubMed ID: 25636819
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Development and Internal Validation of a Model Using Fecal Calprotectin in Combination with Infliximab Trough Levels to Predict Clinical Relapse in Crohn's Disease.
    Roblin X; Duru G; Williet N; Del Tedesco E; Cuilleron M; Jarlot C; Phelip JM; Boschetti G; Flourié B; Nancey S; Peyrin-Biroulet L; Paul S
    Inflamm Bowel Dis; 2017 Jan; 23(1):126-132. PubMed ID: 28002129
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Fecal HMGB1 Reveals Microscopic Inflammation in Adult and Pediatric Patients with Inflammatory Bowel Disease in Clinical and Endoscopic Remission.
    Palone F; Vitali R; Cucchiara S; Mennini M; Armuzzi A; Pugliese D; DʼIncà R; Barberio B; Stronati L
    Inflamm Bowel Dis; 2016 Dec; 22(12):2886-2893. PubMed ID: 27755215
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The diagnostic usefulness of fecal lactoferrin in the assessment of Crohn's disease activity.
    Klimczak K; Lykowska-Szuber L; Eder P; Krela-Kazmierczak I; Stawczyk-Eder K; Szymczak A; Michalak M; Studniarek A; Linke K
    Eur J Intern Med; 2015 Oct; 26(8):623-7. PubMed ID: 26198785
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Detection of Crohn Disease in Patients with Spondyloarthropathy: The SpACE Capsule Study.
    Kopylov U; Starr M; Watts C; Dionne S; Girardin M; Seidman EG
    J Rheumatol; 2018 Apr; 45(4):498-505. PubMed ID: 29449505
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lewis score correlates more closely with fecal calprotectin than Capsule Endoscopy Crohn's Disease Activity Index.
    Koulaouzidis A; Douglas S; Plevris JN
    Dig Dis Sci; 2012 Apr; 57(4):987-93. PubMed ID: 22057284
    [TBL] [Abstract][Full Text] [Related]  

  • 51. EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) study identifies fecal calprotectin, serum MMP9, and serum IL-22 as a novel combination of biomarkers for Crohn's disease activity: role of cross-sectional imaging.
    Faubion WA; Fletcher JG; O'Byrne S; Feagan BG; de Villiers WJ; Salzberg B; Plevy S; Proctor DD; Valentine JF; Higgins PD; Harris JM; Diehl L; Wright L; Tew GW; Luca D; Basu K; Keir ME
    Am J Gastroenterol; 2013 Dec; 108(12):1891-900. PubMed ID: 24126633
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Accurate cut-offs for predicting endoscopic activity and mucosal healing in Crohn's disease with fecal calprotectin.
    Vázquez Morón JM; Pallarés Manrique H; Machancoses FH; Ramos Lora M; Ruiz Frutos C
    Rev Esp Enferm Dig; 2017 Feb; 109(2):130-136. PubMed ID: 28071062
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Fecal calprotectin: a selection tool for small bowel capsule endoscopy in suspected IBD with prior negative bi-directional endoscopy.
    Koulaouzidis A; Douglas S; Rogers MA; Arnott ID; Plevris JN
    Scand J Gastroenterol; 2011 May; 46(5):561-6. PubMed ID: 21269246
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Detection of Small Bowel Mucosal Healing and Deep Remission in Patients With Known Small Bowel Crohn's Disease Using Biomarkers, Capsule Endoscopy, and Imaging.
    Kopylov U; Yablecovitch D; Lahat A; Neuman S; Levhar N; Greener T; Klang E; Rozendorn N; Amitai MM; Ben-Horin S; Eliakim R
    Am J Gastroenterol; 2015 Sep; 110(9):1316-23. PubMed ID: 26215531
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Elevated Faecal Calprotectin Levels are a Reliable Non-Invasive Screening Tool for Small Bowel Crohn's Disease in Patients Undergoing Capsule Endoscopy.
    Yousuf H; Aleem U; Egan R; Maheshwari P; Mohamad J; McNamara D
    Dig Dis; 2018; 36(3):202-208. PubMed ID: 29466790
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis?
    García-Sánchez V; Iglesias-Flores E; González R; Gisbert JP; Gallardo-Valverde JM; González-Galilea A; Naranjo-Rodríguez A; de Dios-Vega JF; Muntané J; Gómez-Camacho F
    J Crohns Colitis; 2010 Jun; 4(2):144-52. PubMed ID: 21122498
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Combined evaluation of biomarkers as predictor of maintained remission in Crohn's disease.
    Sollelis E; Quinard RM; Bouguen G; Goutte M; Goutorbe F; Bouvier D; Pereira B; Bommelaer G; Buisson A
    World J Gastroenterol; 2019 May; 25(19):2354-2364. PubMed ID: 31148906
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Accuracy of fecal calprotectin for the prediction of endoscopic activity in patients with inflammatory bowel disease.
    Jusué V; Chaparro M; Gisbert JP
    Dig Liver Dis; 2018 Apr; 50(4):353-359. PubMed ID: 29396129
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Monitoring and detection of disease recurrence after resection for Crohn's disease: the role of non-invasive fecal biomarkers.
    Yamamoto T; Shimoyama T
    Expert Rev Gastroenterol Hepatol; 2017 Oct; 11(10):899-909. PubMed ID: 28708427
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Correlation of Fecal Markers with Magnifying Endoscopic Stratification in Patients with Ulcerative Colitis Who Are in Clinical Remission.
    Mine S; Takeshima F; Akazawa Y; Matsushima K; Minami H; Yamaguchi N; Ohnita K; Isomoto H; Nakao K
    Digestion; 2018; 97(1):82-89. PubMed ID: 29393146
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.